Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 6:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 280 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Gadolinium Clear all
Completed Phase 4 Interventional

Gadolinium Contrast-enhanced Abbreviated MRI (AMRI) vs. Standard Ultrasound for Hepatocellular Carcinoma (HCC) Surveillance in Patients With Cirrhosis

NCT04288323
View directory record Official record
Conditions
Liver Cancer, Liver Cirrhoses, Liver Carcinoma
Interventions
Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Sep 2, 2026, 6:55 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Efficacy of EVP 1001-1 (SeeMore) in the Assessment of Myocardial Viability in Patients With Cardiovascular Disease

NCT01989195
View directory record Official record
Conditions
ISCHEMIC CARDIOMYOPATHY
Interventions
'SEEMORE' - MANGANESE-ENHANCED MRI CONTRAST REAGENT
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 1, 2017 · Synced Sep 2, 2026, 6:55 AM EDT
Terminated Phase 2 Interventional Results available

Pembrolizumab and Magnetic Resonance Imaging With Ferumoxytol in Treating Patients With Non-small Cell Lung Cancer and Brain Metastases

NCT03325166
View directory record Official record
Conditions
Lung Carcinoma Metastatic in the Brain, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions
Ferumoxytol, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Pembrolizumab
Drug · Other · Procedure + 1 more
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 9, 2022 · Synced Sep 2, 2026, 6:55 AM EDT
Completed Phase 1 Interventional Results available

Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Detecting Lactate and Bicarbonate in Participants With Central Nervous System Tumors

NCT03565367
View directory record Official record
Conditions
Malignant Central Nervous System Neoplasm, Metastatic Malignant Neoplasm in the Central Nervous System
Interventions
Gadolinium, Hyperpolarized Carbon C 13 Pyruvate, Magnetic Resonance Imaging, Magnetic Resonance Spectroscopic Imaging
Other · Drug · Procedure
Lead sponsor
Daniel M. Spielman
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced Sep 2, 2026, 6:55 AM EDT
Withdrawn No phase listed Observational

High-Field MRI Iron-Based Contrast-Enhanced Characterization of Multiple Sclerosis and Demyelinating Diseases

NCT01973517
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Feraheme, Gadolinium-based contrast
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
2
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 9, 2018 · Synced Sep 2, 2026, 6:55 AM EDT
Completed Not applicable Interventional Results available

FMISO PET Study of Glioblastoma

NCT02076152
View directory record Official record
Conditions
Recurrent Glioblastoma
Interventions
FMISO PET, MRI, Bevacizumab, CCNU
Device · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 29, 2021 · Synced Sep 2, 2026, 6:55 AM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Development and Evaluation of Magnetic Resonance Imaging Acquisition and Analysis Methods

NCT02091518
View directory record Official record
Conditions
Healthy
Interventions
MR Screening Questionnaire, Magnetic Resonance Imaging Acquisition and Analysis
Behavioral · Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
672 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 2, 2026, 6:55 AM EDT
Completed Not applicable Interventional

Advanced Cardiac Imaging To Predict Embolic Stroke On Brain MRI: A Pilot Study

NCT04769310
View directory record Official record
Conditions
Atrial Fibrillation, Stroke, Stroke, Cardiovascular, Vascular Cognitive Impairment, Strokes Thrombotic, Stroke, Ischemic
Interventions
Cardiac and Brain MRI
Device
Lead sponsor
Tulane University
Other
Eligibility
18 Years to 120 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Sep 2, 2026, 6:55 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Diagnostic Study of Quantitative Imaging and Spectroscopy in Patients With Multiple Sclerosis

NCT00006060
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
standard gadolinium contrast
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
20 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 1999
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 11, 2009 · Synced Sep 2, 2026, 6:55 AM EDT
Completed Early Phase 1 Interventional

Myocardial Perfusion Magnetic Resonance Imaging Using Regadenoson

NCT00881218
View directory record Official record
Conditions
Ischemic Heart Disease
Interventions
Regadenoson
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 9, 2012 · Synced Sep 2, 2026, 6:55 AM EDT
Recruiting Phase 2 Interventional

Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance

NCT05692635
View directory record Official record
Conditions
Brain Metastases, Nonsmall Cell Lung Cancer Stage III
Interventions
MRI of the Brain, Blood draws, Quality of Life Questionnaires, Gadolinium
Diagnostic Test · Other · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 2, 2026, 6:55 AM EDT
Completed Phase 2 Interventional Results available

Gadoxetate Enhanced Imaging Study to Detect Prostate Cancer

NCT01867424
View directory record Official record
Conditions
Prostate Cancer
Interventions
Eovist
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 7, 2020 · Synced Sep 2, 2026, 6:55 AM EDT
Completed Phase 3 Interventional

Study of Neurologic Progression With Motexafin Gadolinium and Radiation Therapy (SMART)

NCT00054795
View directory record Official record
Conditions
Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Metastases, Neoplasm
Interventions
Motexafin Gadolinium
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
44
States / cities
Phoenix, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 41 more
Source: ClinicalTrials.gov public record
Updated May 7, 2007 · Synced Sep 2, 2026, 6:55 AM EDT
Completed Phase 2 Interventional Results available

Imaging in MGUS, SMM and MM

NCT01237054
View directory record Official record
Conditions
Multiple Myeloma, Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance
Interventions
18-NaF PET, DCE-MRI, 18-FDG PET/CT
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Sep 2, 2026, 6:55 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Nephrogenic Systemic Fibrosis (NSF): Analysis of Tissue Gadolinium Levels

NCT01014754
View directory record Official record
Conditions
Nephrogenic Systemic Fibrosis, Nephrogenic Fibrosing Dermopathy
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
Not listed
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 3, 2014 · Synced Sep 2, 2026, 6:55 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Metabolic Characteristics of Sarcoma In Vivo Using HP 13-C Magnetic Resonance Spectroscopic Imaging (MRSI)

NCT03759704
View directory record Official record
Conditions
Sarcoma, Soft Tissue
Interventions
Hyperpolarized 13CPyruvate
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 3, 2022 · Synced Sep 2, 2026, 6:55 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of Body Mass Index on the Hyperemic Response to Regadenoson

NCT00859833
View directory record Official record
Conditions
Obesity, Endothelial Dysfunction, Decreased Vascular Flow
Interventions
Adenosine, Regadenoson
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 88 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 23, 2011 · Synced Sep 2, 2026, 6:55 AM EDT
Completed Phase 4 Interventional Results available

Post-marketing Safety Study in Patients With Moderate Renal Insufficiency Who Receive Omniscan for Contrast-enhanced Magnetic Resonance Imaging (MRI)

NCT00908310
View directory record Official record
Conditions
Chronic Kidney Disease, Renal Insufficiency
Interventions
Omniscan
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 16, 2014 · Synced Sep 2, 2026, 6:55 AM EDT
Withdrawn Early Phase 1 Interventional

24hr Imaging Of HCC After EOVIST

NCT01968629
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Eovist
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 22, 2015 · Synced Sep 2, 2026, 6:55 AM EDT
Completed Phase 4 Interventional

Dotarem vs Gadobutrol Contrast for Breast MRI

NCT03730051
View directory record Official record
Conditions
Breast Diseases
Interventions
Gadoterate meglumine, Gadobutrol
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Sep 2, 2026, 6:55 AM EDT
Completed Phase 3 Interventional

A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Known or Suspected Brain or Spinal Cord-related Problems

NCT05915702
View directory record Official record
Conditions
Contrast Enhancement in Magnetic Resonance Imaging, Central Nervous System Pathology
Interventions
Gadoquatrane (BAY1747846), Gadobutrol, Gadoterate meglumine, Gadoteridol
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
8
States / cities
Indian Wells, California • Orange, California • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2025 · Synced Sep 2, 2026, 6:55 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Technical and Translational Development of Cardiovascular Magnetic Resonance (CMR) Imaging

NCT03581318
View directory record Official record
Conditions
Normal and Abnormal Cardiovascular Physiology
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
7 Years to 100 Years
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 2, 2026, 6:55 AM EDT
Completed Phase 2 Interventional Results available

Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases

NCT00375830
View directory record Official record
Conditions
Cancer
Interventions
Bone scan, 99mTc-methyl diphosphonate, Positron Emission Tomography (PET) scan, 18F-Fludeoxyglucose (18F-FDG), Computed Tomography (CT) scan, 18F-Sodium Fluoride (18F-NaF), Whole Body Magnetic Resonance Imaging (WB-MRI) scan, Gadopentetate dimeglumine, Gadofosveset, Gadobutrol
Procedure · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2019
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 11, 2023 · Synced Sep 2, 2026, 6:55 AM EDT
Completed Not applicable Interventional

Imaging Correlates of Renal Cell Carcinoma Biological Features

NCT01665703
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
FDG PET/MR
Procedure
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 6, 2021 · Synced Sep 2, 2026, 6:55 AM EDT